Skip to content

Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism

Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03830983
Enrollment
150
Registered
2019-02-05
Start date
2019-03-08
Completion date
2023-01-31
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

Cardioembolic stroke, Cardiac MRI, Heart disease, Vascular disease

Brief summary

The goal of this study is to evaluate left atrial structural and functional abnormalities in stroke of undetected mechanism and atherosclerotic stroke with cardiac MRI.

Detailed description

Aims and objectives: The goal of this study is to evaluate left atrial structural and functional abnormalities in patients with stroke of likely cardio-embolic origin compared with healthy age and sex matches controls and patients with atherosclerotic stroke using cardiac MRI. Background: Despite standard work up for the etiology of ischemic stroke, about 30% of the cases remain unexplained. It is increasingly accepted that these unexplained cases arise from disease outside of the brain. Paroxysmal AF (Atrial fibrillation) may often be suspected as the source but fewer than one third of patients with stroke of undetermined source manifest AF in any form even after 3 years of continuous heart rhythm monitoring. Emerging evidence suggest that atrial functional and structural abnormalities may convey a comparable risk of stroke in which AF is only one of several features. These abnormalities have been termed atrial cardiomyopathy and may be an efficient and practical approach to identify patients at high risk of AF and ischemic stroke. Methods and materials: Cross sectional and prospective cohort study with 3 different groups: 50 patients with stroke of undetected mechanism, 50 patients with atherosclerotic stroke (large or small vessel disease) admitted to the University Hospital of Bispebjerg and Frederiksberg and 50 sex and age matched controls with no history of stroke or AF from the Copenhagen City Heart Study (ØBUS) will be included during a 2 year-period. The study will measure atrial structural abnormalities using cardiac magnetic resonance imaging (MRI) and atrial functional abnormalities by cardiac MRI and echocardiography. A 1 year follow up will examine the incidence of silent brain infarction with MRI and incidence of stroke, atrial fibrillation, acute myocardial infarction and cardiovascular death. Secondary endpoints are to examine the association of functional and structural changes found by MRI with echocardiography, rhythm abnormalities and biomarkers with the purpose of finding clinical easily applicable methods to diagnose atrial cardiomyopathy. Expected outcome and perspectives: The investigators hypothesize that patients with stroke of likely cardio-embolic origin have significantly more atrial fibrotic degeneration and reduced atrial emptying function than patients with atherosclerotic stroke and the control subjects. The investigators expect a higher incidence of silent brain infarction in the group with stroke of likely cardio-embolic origin. With atrial cardiomyopathy investigated thoroughly in patients with stroke of likely cardio-embolic origin the future work-up and treatment strategies could be more efficient and may thus improve the prognosis in terms of mortality and disability for a considerable number of patients.

Interventions

None listed

Sponsors

Rigshospitalet, Denmark
CollaboratorOTHER
Lundbeck Foundation
CollaboratorOTHER
University Hospital Bispebjerg and Frederiksberg
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

(Patients): 1. Stroke of likely cardioembolic cause or of undetected mechanism: Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on MRI. Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings. 2. Large or small vessel stroke (atherosclerotic stroke): Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels \>50% and presence of severe small vessel disease possibly including micro bleeds. 3. Ischemic stroke within 30 days prior to inclusion 4. Age \> 18 years 5. Life expectancy of at least one year 6. Informed consent * Stenosis: % defined by Ultrasound * Small vessel disease: defined according to STRIVE criteria Inclusion Criteria (Controls) 1\. Age and sex matched healthy controls. Matched with the group with stroke of likely cardioembolic stroke.

Exclusion criteria

(Patients): 1. Prior AF or AF \>30 sec on at least 6 hours of monitoring during hospitalization. 2. Other major cardio-embolic risk sources assumed as cause of stroke (e.g. endocarditis, myocardial infarction within last 4 weeks, prosthetic cardiac valve) 3. Contraindications to MRI (Including eGFR\<30 or other contraindications for the contrast agent used during Cardiac MRI) 4. Assumed unable to participate in the study by investigator (including but not restricted to psychiatric condition, dementia)

Design outcomes

Primary

MeasureTime frameDescription
Left Atrial Emptying Function (LAEF)Within 12 weeks from index eventMeasured with gadolinium enhanced cardiac MRI
Extent of the fibrosis in the Left Atrium (LA)Within 12 weeks from index eventMeasured with gadolinium enhanced cardiac MRI

Secondary

MeasureTime frameDescription
Left atrial volumeWithin 12 weeks from index eventAssessed by cardiac MRI
Left atrial appendage morphologyWithin 8 weeks from index eventAssessed by cardiac MRI
Left atrium volumeWithin 12 weeks from index event2D and 3D left atrial volume assessed by transthoracic echocardiography
Left atrium ejection fraction (LAEF)Within 12 weeks from index eventAssessed by transthoracic echocardiography
Speckle tracking of LAWithin 12 weeks from index eventAssessed by transthoracic echocardiography
Heart rate variability (HRV)Within 4 weeks from index eventTime domain variables (meanNN, SDNN, SDANN, SDNNidx, RMSSD, pNN50)
Thrombophilia biomarkersWithin 12 weeks from index eventAssessment of hypercoagulability
Cardiac specific biomarkersWithin 12 weeks from index eventAtrial Natriuretic Peptide, pro NT-Brain Natriuretic Peptide, High Sensitive Troponins.
Inflammatory biomarkersWithin 12 weeks from index eventHigh Sensitive CRP, Interleukins: IL1, IL1b, IL6, IL18
Fibrosis related markersWithin 12 weeks from index eventCollagen type I and III
Atrial rhythm abnormalities: Number of premature atrial contractions (PAC) per hour. Number and length of runs of PACWithin 4 weeks from index eventAssessed by 48-hours Holter monitoring
Observational study: Incidence of silent brain infarctionsBetween 1-2 years from index eventIncidence of silent brain infarctions assessed by follow-up MR-cerebrum (Only in patients)

Other

MeasureTime frameDescription
Observational study: Assessing incidence of stroke, acute myocardial infarction, atrial fibrillation and cardiovascular-death1 year from last included patientFollow up in patient records

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026